论文部分内容阅读
目的探讨阿立哌唑治疗Tourette综合征(TS)临床疗效和安全性。方法 38例TS患者予阿立哌唑(5～20mg/d)治疗,共治疗8周,采用耶鲁抽动严重程度总体量表(YGTSS),副反应量表(TESS),于治疗前,治疗第2、4、8周末对患者进行评估。结果患者第2、4、8周末严重程度得分与治疗前相比有明显下降,差异有极显著性(t=3.214,2.43,3.88;P<0.01)。患者在治疗2、4周末副反应与治疗前相比差异有显著性(t=6.02,4.80;P<0.05)。而第8周末与治疗前相比差异无显著性(t=1.09,P>0.05)。结论阿立哌唑能有效改善运动及发生抽动,副作用较轻。
Objective To investigate the clinical efficacy and safety of aripiprazole in the treatment of Tourette’s syndrome (TS). Methods Thirty-eight patients with TS were treated with aripiprazole (5 ~ 20mg / d) for 8 weeks. The total Yale TSV and TESS were measured before and after treatment. Patients were evaluated at 2, 4 and 8 weeks. Results At the end of the 2nd, 4th, and 8th week, the scores of severity of patients decreased significantly compared with those before treatment (t = 3.214,2.43,3.88; P <0.01). There was a significant difference in side effects between the two groups at the end of 2 and 4 weeks (t = 6.02, 4.80; P <0.05). However, the difference between the 8th weekend and before treatment was not significant (t = 1.09, P> 0.05). Conclusion Aripiprazole can effectively improve the movement and twitch with less side effects.